文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

凝血酶原时间国际标准化比值与白蛋白比值对合并脓毒症的癌症患者预后意义:一项回顾性队列研究

Prognostic Significance of the Prothrombin Time-International Normalized Ratio to Albumin Ratio in Cancer Patients with Complication of Sepsis: A Retrospectively Cohort Study.
PubMed 文献 · Shock · 2026-01-28
一句话结论在合并脓毒症的癌症患者中,入ICU时PTAR独立预测28天死亡率,判别能力优于SOFA和INR,可作为现有评分系统的补充生物标志物。

该回顾性队列研究利用MIMIC-IV数据库1584例成人癌症合并脓毒症ICU患者及中国某三级肿瘤医院82例患者,分析凝血酶原时间国际标准化比值与白蛋白比值(PTAR)对28天和365天全因死亡率的预测价值。MIMIC-IV队列中PTAR最高四分位组(Q4)28天死亡风险 adjusted HR=2.038、365天 adjusted HR=1.615;中国队列中PTAR亦预测28天死亡率 adjusted HR=4.682。PTAR在两个队列中对28天死亡率的判别能力均优于SOFA评分和INR,中国队列AUC 0.721 vs SOFA 0.564。作者认为PTAR可作为补充生物标志物与现有临床评分系统和实验室指标联合使用。

要点

  • MIMIC-IV队列中PTAR最高四分位组(Q4)28天死亡风险 adjusted HR=2.038,365天 adjusted HR=1.615。
  • 中国队列中PTAR预测28天死亡率 adjusted HR=4.682,AUC 0.721优于SOFA的0.564。
  • PTAR在28天和365天两个时间点的判别能力均优于SOFA评分和INR。
  • 365天死亡率仅在MIMIC-IV队列中得到验证,该队列中PTAR预测性能强于INR和SOFA。
  • 作者认为PTAR可作为补充生物标志物,与现有临床评分系统和实验室指标联合使用,为癌症合并脓毒症提供额外风险信息。

适用人群与场景

  • MIMIC-IV数据库中的1584例成人癌症合并脓毒症ICU患者。
  • 中国某三级肿瘤医院的82例癌症合并脓毒症患者。

研究设计与关键结果

  • 研究类型为回顾性队列研究,MIMIC-IV队列1584例,中国队列82例。
  • MIMIC-IV队列中PTAR最高四分位组(Q4)28天死亡率 adjusted HR=2.038,365天死亡率 adjusted HR=1.615。
  • 中国队列中PTAR预测28天死亡率 adjusted HR=4.682,AUC 0.721优于SOFA的AUC 0.564。
  • PTAR在28天和365天两个时间点的判别能力均优于SOFA评分和INR。
  • 365天死亡率仅在MIMIC-IV队列中得到验证,该队列中PTAR预测性能强于INR和SOFA。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为PTAR可作为补充生物标志物,与现有临床评分系统和实验室指标联合使用,为癌症合并脓毒症提供额外风险信息。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Accumulating evidence supports the use of the prothrombin time-international normalized ratio-to-albumin ratio (PTAR) as a prognostic biomarker in various diseases. This study evaluated whether PTAR, an easily measurable index, predicts short- and long-term all-cause mortality in cancer patients with sepsis (cancer sepsis).

METHODS: This retrospective cohort study used data from 1,584 adult cancer-sepsis patients in the intensive care unit from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database (v3.1) and 82 patients from a Chinese tertiary oncology hospital. Mortality at 28 and 365 days was analyzed using multivariable Cox models, restricted cubic splines, Kaplan-Meier curves, and subgroup analyses. Discriminatory performance was assessed with the area under the receiver operating characteristic curve (AUC), comparing PTAR with the Sequential Organ Failure Assessment (SOFA) score, international normalized ratio (INR), and serum albumin (ALB). AUC differences were tested using DeLong's test.

RESULTS: In the MIMIC-IV cohort, patients in the highest PTAR quartile (Q4) had significantly higher risks of 28-day (adjusted heart rate = 2.038) and 365-day mortality (adjusted heart rate = 1.615). PTAR showed superior discrimination compared with the SOFA score and INR at both time points. In the Chinese cohort, PTAR also predicted 28-day mortality (adjusted heart rate = 4.682), with better AUC (0.721) than SOFA (0.564).

CONCLUSIONS: PTAR at intensive care unit admission independently predicts 28-day mortality in cancer patients with sepsis in both the MIMIC-IV and Chinese cohorts, outperforming SOFA and INR. The 365-day mortality was validated only in the MIMIC-IV cohort, where PTAR demonstrated stronger predictive performance compared with INR and SOFA. Therefore, PTAR can serve as a complementary biomarker to be used in conjunction with existing clinical scoring systems and laboratory indicators, providing additional risk assessment information for cancer-sepsis.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Wang T, Liu D, Niu F, et al. Prognostic Significance of the Prothrombin Time-International Normalized Ratio to Albumin Ratio in Cancer Patients with Complication of Sepsis: A Retrospectively Cohort Study. Shock. 2026. PMID: 41593846. doi:10.1097/SHK.0000000000002797

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。